Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control

The aim of this evaluation was to identify the first indicators of efficacy for 225Ac-labeled prostate-specific membrane antigen (PSMA)-617 therapy in a retrospectively analyzed group of patients.

Saved in:

Bibliographic Details
Main Authors:	Kratochwil, Clemens (Author) , Bruchertseifer, Frank (Author) , Rathke, Hendrik (Author) , Hohenfellner, Markus (Author) , Giesel, Frederik L. (Author) , Haberkorn, Uwe (Author) , Morgenstern, Alfred (Author)
Format:	Article (Journal)
Language:	English
Published:	Jan. 11, 2018
In:	Journal of nuclear medicine Year: 2018, Volume: 59, Issue: 5, Pages: 795-802
ISSN:	2159-662X
DOI:	10.2967/jnumed.117.203539
Online Access:	Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.2967/jnumed.117.203539 Verlag, lizenzpflichtig, Volltext: http://jnm.snmjournals.org/content/59/5/795
Author Notes:	Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Markus Hohenfellner, Frederik L. Giesel, Uwe Haberkorn, and Alfred Morgenstern

Description
Summary:	The aim of this evaluation was to identify the first indicators of efficacy for 225Ac-labeled prostate-specific membrane antigen (PSMA)-617 therapy in a retrospectively analyzed group of patients.
Item Description:	Im Titel erscheint die Ziffernfolge 225 hochgestellt Gesehen am 16.04.2020
Physical Description:	Online Resource
ISSN:	2159-662X
DOI:	10.2967/jnumed.117.203539